scholarly journals Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer’s disease

2011 ◽  
Vol 3 (7) ◽  
pp. 821-833 ◽  
Author(s):  
Michael Voronkov ◽  
Steven P Braithwaite ◽  
Jeffry B Stock
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Phosphoprotein Phosphatase ◽  
Phosphatase 2A

scholarly journals Protein phosphatase 2A, complement component 4, and APOE genotype linked to Alzheimer’s disease using a systems biology approach

2020 ◽  
Author(s):  
Gyungah R. Jun ◽  
Yang You ◽  
Congcong Zhu ◽  
Gaoyuan Meng ◽  
Jaeyoon Chung ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prefrontal Cortex ◽  
Protein Phosphatase ◽  
Gene Network ◽  
Protein Phosphatase 2A ◽  
Tau Pathology ◽  
Culture Experiment ◽  
Protein Levels ◽  
Phosphatase 2A

ABSTRACTBackgroundRecent reports suggest that the rare apolipoprotein E (APOE) Christchurch mutation and ε2 allele protect against Alzheimer’s disease (AD) pathology by reducing the burden of tau pathology. However, the mechanism(s) underlying the ε2 protective effect linking to tau is largely unknown.MethodsThe role of the ε2 allele in Alzheimer’s disease (AD) was investigated a genome-wide association study (GWAS) for AD among 2,120 ε2 carriers from the Alzheimer Disease Genetics Consortium (ADGC), and then prioritized by gene network analysis, differential gene expression analysis at tissue- and cell-levels as well as methylation profiling of CpG sites, in prefrontal cortex tissue from 761 brains of the Religious Orders Study and Memory and Aging Project (ROSMAP) and the Framingham Heart Study (FHS), Boston University Alzheimer’s Disease Center (BUADC). The levels of two catalytic subunit proteins from protein phosphatase 2A (PPP2CA and PPP2CB) were validated in prefrontal cortex area of 193 of the FHS/BUADC brains. The findings from human autopsied brains were further validated by a co-culture experiment of human isogenic APOE induced pluripotent stem cell (iPSC) derived neurons and astrocytes.ResultsOf the significantly associated loci with AD among APOE ε2 carriers (P<10−6), PPP2CB (P=1.1×10−7) was the key node in the APOE ε2-related gene network and contained the most significant CpG site (P=7.3×10−4) located 2,814 base pair upstream of the top-ranked GWAS variant. Among APOE ε3/ε4 subjects, the level of Aβ42 was negatively correlated with protein levels of PPP2CA (P=9.9×10−3) and PPP2CB (P=2.4×10−3), and PPP2CA level was correlated with the level of pTau231 level (P=5.3×10−3). Significant correlations were also observed for PPP2CB with complement 4B (C4B) protein levels (P=3.3×10−7) and PPP2CA with cross reactive protein (CRP) levels (P=6.4×10−4). C1q level was not associated with Aβ42, pTau231, PPP2CB, or C4B levels. We confirmed the significant correlation of PPP2CB expression with pTau231/tTau ratio (P=0.01) and C4A/B (P=2.0×10−4) expression observed in brain tissue in a co-culture experiment of iPSC derived neurons and astrocytes.ConclusionWe demonstrated for the first time a molecular link between a tau phosphatase and the classical complement pathway, especially C4, and AD-related tau pathology.

O4-04-04: A protein phosphatase-2A-based etiopathogenic mechanism of Alzheimer's disease

2010 ◽  
Vol 6 ◽  
pp. S155-S155
Author(s):  
Khalid Iqbal ◽  
Xiaochuan Wang ◽  
Julie Blanchard ◽  
Inge Grundke-Iqbal
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Phosphatase 2A
Sign in / Sign up

Export Citation Format

Share Document